Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CBD 40 mg Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 7, 2026, 8:38 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

NCT04550377
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 7, 2026, 8:38 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

NCT03458416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710
View directory record Official record
Conditions
Abuse, Drug, Pain
Interventions
Placebo, THC, CBD 20 mg, CBD 40 mg, CBD 80 mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

NCT02324673
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 7, 2026, 8:38 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

NCT02844933
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Tucson, Arizona • San Diego, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 7, 2026, 8:38 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731
View directory record Official record
Conditions
Spasms, Infantile
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
6 Months to 36 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

NCT00660673
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy® 1400 ambulatory infusion pump, Percutaneous Endoscopic Gastrostomy with jejunal extension tube (PEG-J)
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years to 99 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cannabidiol and Focus Study (CBD-Focus)

NCT05189275
View directory record Official record
Conditions
Healthy
Interventions
Daily Beverage Intervention
Dietary Supplement
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Greeley, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

NCT05098509
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

NCT02318602
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Pharmacological Agents for Chronic Spinal Cord Injury (SCI)

NCT05708274
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
CPH + hand training, CD-LD + hand training, ATX + hand training, Placebo + hand training
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim

NCT04970342
View directory record Official record
Conditions
Driving Behavior, Driving Under the Influence
Interventions
Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD)
Drug
Lead sponsor
Timothy L. Brown
Other
Eligibility
19 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

NCT00199420
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 4 Interventional

Istradefylline Effect Protocol on Parkinson's Disease Tremor

NCT05885360
View directory record Official record
Conditions
Parkinson Disease, Tremor
Interventions
Istradefylline Pill
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
McLean, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

NCT02953548
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 2 Interventional

12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

NCT00456586
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002 (istradefylline)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 7, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 7, 2026, 8:38 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Improving Therapeutic Learning for PTSD

NCT04558112
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder
Interventions
L-DOPA, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Austin, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 7, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 7, 2026, 8:38 AM EDT